Category: Pharmaceuticals
The trial would be funded entirely by MediciNova The result of a successful pivotal trial would lead to the Phase 2b/3 efficacy and safety data support a New Drug Application (NDA) MediciNova, Inc., a biopharmaceutical firm, has reportedly announced that the U.S. Food and Drug …
The portfolio in question includes over 30 generic injectable products. The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …
AstraZeneca and U.S. partner MSD Inc. have made it to the headlines for winning European Commission’s approval for Lynparza (olaparib), their blockbuster candidate originated and developed in Cambridge for the treatment of breast Cancer. As per trusted sources, the candidate has been backed by the …
One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …
The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …
Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …
The study will evaluate the combination of NEO-PV-01 with nivolumab (anti-PD-1 therapy) in metastatic or advanced melanoma patients Neon Therapeutics Inc., an immuno-oncology company which develops neoantigen-based treatments has reportedly presented updated data that describes pathologic and immune markers related with durable clinical advantages in …
The approval resulted from reviewing the data from the phase 3 ‘DEPICT’ clinical programme and also a dedicated trial in patients in Japan AstraZeneca recently announced that Forxiga (dapagliflozin) as an oral supplement treatment to insulin for adults having type-1 diabetes has won approval from …
The clinical data would be coming from the company’s phase-2 ampreloxetine clinical trials. The 20-week-long data supports a previously announced medical observation after approximately four weeks of therapy. Theravance Biopharma, Inc., (Theravance Biopharma), a renowned diversified biopharmaceutical company, has reportedly announced the outcome of the …
